Quick Answer
Oric Pharmaceuticals, Inc. reported Net Income Loss of -$129.47 million for the year ending 2025.
- Oric Pharmaceuticals, Inc. showed a decrease of -1.3% in Net Income Loss from 2024 to 2025.
- This data is from Oric Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$6.02 million | Q2 2019: -$5.97 million | Q3 2019: -$6.55 million | Q1 2020: -$8.87 million | Q2 2020: -$11.02 million | Q3 2020: -$25.55 million | Q1 2021: -$16.51 million | Q2 2021: -$21.01 million | Q3 2021: -$18.43 million | Q1 2022: -$23.16 million | Q2 2022: -$20.29 million | Q3 2022: -$24.83 million | Q1 2023: -$23.95 million | Q2 2023: -$22.94 million | Q3 2023: -$25.48 million | Q1 2024: -$25.01 million | Q2 2024: -$31.96 million | Q3 2024: -$34.57 million | Q1 2025: -$30.02 million | Q2 2025: -$36.36 million | Q3 2025: -$32.59 million.
- Over the full 8 years of available data (2018 to 2025), Oric Pharmaceuticals, Inc.'s Net Income Loss has declined by 506.0%.
- Historical annual values: Fiscal year 2025: -$129.47 million | Fiscal year 2024: -$127.85 million | Fiscal year 2023: -$100.70 million | Fiscal year 2022: -$89.12 million | Fiscal year 2021: -$78.72 million | Fiscal year 2020: -$73.70 million | Fiscal year 2019: -$26.88 million | Fiscal year 2018: -$21.36 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: